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Abstract
With the introduction of novel oral anticoagulants (NOACs), the factors driving anticoagulant 
selection in atrial fibrillation (AF) in real-world practice are unclear. The goal was to examine 
whether and to what extent utilization has been driven by predictions of stroke risk (treatment 
benefit), bleeding risk (treatment harm), or prescription benefits’ coverage. We extracted a cohort 
of non-valvular AF patients initiating anticoagulation from Oct 2010-Dec 2012 from a large US 
database of commercial and Medicare supplement claims. Multivariable regression examined 
associations between ischemic stroke (CHA2DS2-VASc) and bleeding (ATRIA) risk scores and 
benefits’ generosity (proportion of costs covered by patients relative to total) with warfarin and 
NOAC selection and also between dabigatran and rivaroxaban. C-statistics and partial chi-square 
statistics were used to assess the variation explained. Of 70,498 patients initiating anticoagulation, 
29.9% and 7.9% used dabigatran and rivaroxaban, respectively. Compared with warfarin, patients 
were less likely to receive a NOAC with high ischemic stroke risk (CHA2DS2-VASc ≥2) 
(Adjusted Relative Risk [aRR]: 0.75, 95% CI: 0.72-0.77) and high bleeding risk (ATRIA≥5) 
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(aRR: 0.66, 95% CI: 0.64-0.69) but more likely with good benefits’ generosity (≤20% of costs 
borne by patient) (aRR: 2.03, 95% CI: 1.92-2.16). Prescription generosity explained almost twice 
the model variation as either risk score. Compared with dabigatran, patients were more likely to 
fill rivaroxaban with high bleeding risk (aRR: 1.16, 95% CI: 1.09-1.24). In conclusion, patients 
with higher bleeding and ischemic stroke risk were more likely to initiate warfarin, but generous 
benefits more strongly predicted NOAC usage and drove more selection.
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INTRODUCTION
For decades, warfarin had been the primary oral anticoagulant for patients with atrial 
fibrillation (AF).1 Recent availability of novel oral anticoagulants (NOACs) provided 
additional options.2,3,4 It is unclear the extent to which risk of ischemic stroke, bleeding risk, 
or prescription benefits’ generosity may affect anticoagulant selection in clinical practice, 
particularly with these newer anticoagulant options available. Therefore, the goal of this 
study is to investigate whether and to what extent anticoagulant selection in AF patients has 
been driven by clinical predictions of treatment benefit and harm and prescription benefits’ 
generosity in a large national real-world US database. We sought to 1) assess the 
associations of predictions of ischemic stroke risk, bleeding risk, and benefits’ generosity 
with warfarin selection versus NOACs, 2) assess these factors’ associations with selection 
between dabigatran and rivaroxaban, and 3) explore the extent of the variation in 
anticoagulant selection driven by these factors.
METHODS
This is a retrospective cohort study using the Truven Health MarketScan® Commercial 
Claims and Encounters and Medicare supplement databases for the years 2009-2012. These 
data files include patient-specific medical inpatient and outpatient claims, physician office 
visits, outpatient pharmaceutical data and enrollment data with an encrypted unique patient 
identifier from over 100 nationwide insurers for approximately 40 million individuals 
annually. These databases were linked using the encrypted patient identifier to ensure that 
each patient was only included once. Prescription medication use was identified through 
National Drug Codes (NDCs) in the prescription files, including anticoagulants.
A cohort of AF patients was selected based on the following inclusion criteria: 1) filling ≥ 1 
prescription for warfarin or a NOAC (dabigatran or rivaroxaban) after 10/19/2010 
(dabigatran FDA approval date), hereafter referred to as the “index fill”; 2) ≥ 18 years of 
age; 3) receiving at least 1 inpatient or 2 outpatient International Classification of Diseases, 
9th edition (ICD-9) codes for AF (ICD-9: 427.31) occurring on separate days within 12 
months prior to the index fill date (1 outpatient claim could occur after the index date); and 
4) were continuously enrolled for ≥12 months prior to the index fill. The first fill of any of 
these anticoagulants after 10/19/2010 was designated as the index fill. The 2 ICD-9 codes 
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were required on separate days to eliminate the possibility of the code used as a rule-out 
condition.
Patients were excluded from the study if they had an anticoagulant prescription fill in the 12 
months prior to the index fill to examine new anticoagulation users. Because dabigatran and 
rivaroxaban are only indicated in non-valvular AF, patients with ICD-9 codes corresponding 
to valvular and transient AF in the 12-month baseline were excluded to ensure appropriate 
comparisons (Appendix Table 1). These exclusions are similar to those used in trials for 
FDA approval and in previous studies, including patients with valve replacements, 
coagulation deficiencies, liver disease, atrial flutter, or hyperthyroidism.5-7
Ischemic stroke and bleeding risk were measured in the 12 months prior to anticoagulation 
initiation using ICD-9 codes in the inpatient and outpatient claims files based on previously-
used algorithms (Appendix Table 1).8,9 Ischemic stroke risk was calculated through the 
CHA2DS2-VASc score, which incorporates congestive heart failure (+1), hypertension (+1), 
age 65-74 years (+1), age ≥75 years (+2), diabetes (+1), prior ischemic stroke (+2), female 
gender (+1), coronary artery disease (+1), and peripheral vascular disease (+1). Following 
guideline conventions, the CHA2DS2-VASc score was categorized into three levels: 0 (low 
risk), 1 (intermediate risk), and ≥2 (high risk). Bleeding risk was measured through the 
Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) score, which includes 
anemia (+3), severe renal disease (+3), age ≥75 years (+2), previous hemorrhage (+1), and 
hypertension (+1). The ATRIA score was categorized as follows: ≤3 (low risk), 4 
(intermediate risk), and ≥5 (high risk), conforming to previously validated standards. Of the 
bleeding clinical prediction risk scores, the ATRIA score is considered to be more reliably 
measured in secondary medical claims.10,9,11
Because overall copayment burden may influence a patient's predisposition towards a certain 
therapy, the patients’ cost-sharing proportion for all prescriptions in the 12 months prior to 
the index fill divided by total drug payments was calculated as a benefits’ generosity 
measure.12 This proportion was categorized into three levels paid by patients: > 0.80 (“No/
Poor coverage”), 0.20-0.80 (“Fair coverage), and ≤ 0.20 (“Good coverage”). In other words, 
at the “No/poor coverage” level, more than 80% of the actual prescription costs over the 
previous 12 months were covered by patients out of the total paid.
Patient demographic characteristics thought to be associated with anticoagulation and not 
already included in the risk scores were identified in the 12-month baseline, including region 
of residence (north central, northeast, south, west) and type of health plan (comprehensive, 
health maintenance organization, point-of-service, preferred provider organization, 
consumer-driven health plan). In addition to those in the risk scores, other comorbidities 
were identified in the baseline period using ICD-9 codes in the outpatient or inpatient claims 
based on previous literature, including venous thromboembolism (VTE), peptic ulcer 
disease, hyperlipidemia, dementia and sleep apnea. Concomitant medications with known 
associations with anticoagulation were also measured, including antiplatelets, 
gastroprotective agents, antiarrhythmics, rate control therapies (e.g., digoxin, beta-blockers, 
calcium channel blockers), and statins.
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In the analytic plan, sociodemographic and clinical characteristics among patients receiving 
anticoagulation were described, examining their association with the selection of warfarin 
and newer anticoagulants. Multivariable modified Poisson regression models were used to 
examine the associations between the CHA2DS2-VASc score, ATRIA score and benefits’ 
generosity and anticoagulant selection. Multivariable modified Poisson regression models 
generate the estimated relative risk (RRs) with robust standard errors.13 Two multivariable 
models were constructed. We first modeled the selection of NOACs compared with 
warfarin. Next, we predicted the selection of rivaroxaban with dabigatran as the referent 
group, restricting analysis to when both agents were FDA-approved for AF (after 
11/4/2011). These models were adjusted for all measured patient baseline characteristics not 
already included in the clinical prediction risk scores to avoid colinearity. We conducted a 
number of sensitivity analyses adjusting for calendar quarter, stratifying before and after 
Nov 2011 in the analyses, including patients diagnosed with AF within 60 days after the 
index fill date, and including gender as a covariate alongside the risk scores. To assess the 
extent of selection driven by the risk scores and benefits’ generosity measures, c-statistics 
were applied to examine how the prediction of the anticoagulant selection may be changed 
by removing the variable of interest (e.g., risk scores and benefits’ generosity) from the full 
model. In addition, partial chi-square tests were used to compare the strength of these 
variables of interest in predicting anticoagulant selection and the proportion of model 
variance explained relative to the full model chi-square.14 Statistical significance was 
determined using 2-sided tests with alpha=0.05. All analyses were conducted using SAS 9.3 
(Cary, NC). The UNC Institutional Review Board approved this study.
RESULTS
In total, 70,498 AF patients met study criteria (Figure 1). Of these, 43,865 (62%) used 
warfarin, 21,070 (30%) used dabigatran and 5,563 (8%) used rivaroxaban. Measured 
baseline characteristics of the AF patients beyond the risk scores are provided in Table 1. 
The mean age of the cohort was 70 years (standard deviation [SD] 12), and 42,334 (60%) 
were male. Patients using warfarin for the first time were also more likely to have 
experienced relevant comorbidities, particularly ischemic stroke, congestive heart failure, 
and VTE. Compared with warfarin, new users of dabigatran and rivaroxaban had lower 
mean ischemic stroke and bleeding risk scores but had better benefits’ generosity in the 
previous 12 months (Table 2). Patients who were newly-initiating anticoagulation with 
rivaroxaban had greater bleeding risk than dabigatran but slightly lower ischemic stroke risk 
and similar benefits’ generosity. Patients receiving warfarin were more likely to have lower 
benefits’ generosity compared with NOAC users.
The multivariable regression models indicate that clinical predictions of risk are associated 
with selecting a particular anticoagulant in treatment-naïve AF patients. Table 3 shows the 
relative risk predictions of anticoagulant treatment selection adjusted for all model 
covariates for the 3 primary variables of interest (bleeding risk, ischemic stroke risk, and 
benefits’ generosity). The relative risks and 95% CIs for the full model including all 
covariates are shown in Appendix Table 2. Ischemic stroke and bleeding risk predictions 
were associated with anticoagulant selection even after adjusting for all other measured 
baseline characteristics not already included in the risk scores. In particular, high ischemic 
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stroke risk was associated with selecting warfarin as opposed to a NOAC. Patients at high 
ischemic stroke risk (CHA2DS2-VASc ≥2) were 25% less likely to receive a NOAC 
compared with warfarin. Clinical predictions of bleeding risk were also associated with 
warfarin selection. Patients at high bleeding risk (ATRIA ≥5) were 34% less likely to 
receive a NOAC compared with warfarin. Moreover, patients with good benefits’ generosity 
in the previous 12 months were more than 2 times as likely to fill a NOAC compared with 
warfarin. Among patients initiating NOACs, the likelihood of filling rivaroxaban compared 
with dabigatran was also examined (Table 3). After adjusting for measured covariates, 
patients with high ischemic stroke risk were no less likely to initiate rivaroxaban compared 
with dabigatran. By contrast, patients with high bleeding risk were 16% more likely to 
initiate rivaroxaban compared with dabigatran. Lastly, having good prescription benefits in 
the previous 12 months was also not associated with selection of either NOAC. In the 
sensitivity analyses, the results were not substantively changed. A description of the 
sensitivity analyses and corresponding results is provided in Appendix Table 3.
For the analysis comparing NOACs to warfarin, the extent of variation in anticoagulant 
selection was not largely driven by the risk scores (Table 4). However, the benefits’ 
generosity was relatively more predictive of anticoagulant selection than either risk score 
(e.g., change in c-statistic: -0.013 for benefits’ generosity vs. -0.009 for ATRIA or -0.008 for 
CHA2DS2-VASc). Benefits’ generosity also had the highest partial chi-square (explaining 
14% of the total model variation); however, no variable accounted for a large proportion of 
the total chi-square of the full model. For the analysis comparing rivaroxaban to dabigatran, 
none of the variables of interest added considerable prediction to anticoagulant selection, 
although prediction of bleeding was the strongest factor (change in c-statistic: -0.004 for 
ATRIA vs. -0.001 for CHA2DS2-VASc or benefits’ generosity). In addition, the c-statistic 
for the full rivaroxaban vs. dabigatran model was also relatively low (0.557). The ATRIA 
score had the relative highest partial chi-square in selecting between rivaroxaban and 
dabigatran (explaining 14% of the total model variation).
DISCUSSION
In this large study of AF patients initiating anticoagulation, we found strong associations 
between ischemic stroke risk, bleeding risk, and prescription benefits’ generosity and 
anticoagulant selection. Patients with high ischemic stroke risk and bleeding risk were much 
less likely to initiate a NOAC versus warfarin. However, the extent of anticoagulant 
selection driven independently by ischemic stroke risk (predictions of treatment benefit) and 
bleeding risk (prediction of treatment harm) was marginal, as neither score explained much 
variation in the multivariable adjusted regression model. By contrast, benefits’ generosity 
was strongly associated with anticoagulant selection, even after adjusting for all other 
measured covariates and appeared to drive anticoagulant selection more strongly than 
ischemic stroke or bleeding risk predictions. Among NOAC initiators, we also found that 
patients initiating rivaroxaban had higher bleeding risk scores than patients initiating 
dabigatran, but patients using dabigatran had higher ischemic stroke risk scores. The 
generosity of the prescription benefit slightly differed between the NOACs, and none of the 
variables of interest drove much variation in selection between NOACs.
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These results concur in part with previous research suggesting that some selection (or 
channeling) away from dabigatran has occurred, particularly in patients with high ischemic 
stroke and bleeding risk.15,16 While these studies were generally small in sample size or 
limited to younger patients, they too found that patients newly-initiating dabigatran had 
lower bleeding risk and fewer comorbidities. However, in contrast to a recent study 
published by Steinberg et al., we found that bleeding risk was more strongly associated with 
initial anticoagulant selection than ischemic stroke risk.17 Their study found an overall lack 
of familiarity with bleeding risk guidelines by physicians for patients enrolled in a registry; 
however, the study did not examine rivaroxaban or the contribution of patients’ prescription 
benefits. By contrast, the results in our study suggest that physicians may already selectively 
prescribe NOACs for patients at lower risk of bleeding. However, to our knowledge, no 
study has yet examined the concurrent influence of treatment benefit, risks, and cost-sharing 
on the decision of treatment selection, nor yet conducted a similar examination of 
characteristics in such a large, nationwide database.15,16
The large randomized-controlled trials used for initial approval of the NOACs broadly found 
similar efficacy in preventing ischemic stroke and systemic embolism between NOACs and 
warfarin but significantly better safety, particularly in reducing intracranial bleeding and 
hemorrhagic stroke.4,6,7 Our results suggest that clinicians may be differentially choosing 
warfarin in real-world clinical practice for patients with both high stroke risk and bleeding 
risk, indicating possible concerns about the lack of a reversal agent for the NOACs. Future 
research needs to continue to address this concern.
More importantly, while both ischemic stroke risk and bleeding risk were associated with 
overall anticoagulant selection, neither factor largely drove selection, but instead, selection 
was relatively driven more by benefits’ generosity. This observation has important 
implications for the process and outcomes of treatment decision-making in clinical practice. 
Though clinical guidelines recommend that clinicians weigh the balance of benefit with the 
risk of harm of available treatment options,2,18 our study showed that benefits’ generosity 
was a much more important factor driving anticoagulant selection in practice, even though 
previous studies have found that provider-patient discussions on prescription costs are often 
limited.19,20 Moreover, high treatment costs and low insurance coverage may also affect 
patient adherence. Previous research in other contexts has shown that high patient cost-
sharing burden can lead to lower medication adherence and high rates of medication 
discontinuation21,22, which in this setting could leave AF patients at high risk of stroke. 
Further research may be necessary to confirm these observations.
In addition, overall stroke risk, bleeding risk, prescription benefit and other patient 
characteristics in our analyses drove little variation in anticoagulant selection between 
NOACs and warfarin (the c-statistics ranged from 0.66 to 0.68). The large unexplained 
variation in treatment selection among anticoagulant initiators may indicate that possible 
clinical equipoise exists between the selection of NOACs and warfarin. The treatment 
selection may be in large part influenced by clinicians through preferences or other factors 
unrelated to patient clinical or prognostic characteristics. Recent guidelines from the 
American Heart Association/American College of Cardiology/Heart Rhythm Society 
(AHA/ACC/HRS) suggested that clinical equipoise may exist between all the anticoagulants 
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for patients at high risk of stroke.2 This possible clinical equipoise may be exploited to 
assess the comparative effectiveness of different anticoagulants, particularly among the 
NOAC initiators.
Our study has several strengths and limitations. First, prescription refill records from 
commercial claims databases may not fully reflect medication use. However, prescription 
refill records have been shown to have good validity, correlation, and similar sensitivity/
specificity as other measurements, including self-report, pill counts, and electronic 
records.23,24 Some warfarin fills may also not be captured due to market influences and cash 
payments, such as low-cost generic programs in pharmacies.25,26 The ATRIA score has 
been used less frequently but has been shown to be better validated in claims data.9,11 While 
we could not measure provider preferences directly or cluster by provider, our study sought 
to disentangle how patient characteristics influenced selection. As for strengths, our study 
used a large database of nationally-representative commercially-insured patients, including 
some Medicare beneficiaries. To our knowledge, most previous research examining the 
NOACs has been conducted in Europe or smaller databases. In addition, this study studied 
both dabigatran and rivaroxaban a full 2 years after NOAC availability. Lastly, while the 
clinical prediction risk scores have been thought to be only moderately associated with the 
true risk of outcomes in AF, the CHA2DS2-VASc has been thought to have better real-world 
concordance than the CHADS2 and could be considered a strength of our study.
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Figure 1. Cohort Flow Diagram for identification of the cohort
The flow diagram for the selection of the patients with atrial fibrillation (AF) newly-
initiating therapy is shown. Of the 412,448 patients who filled ≥1 anticoagulant prescription, 
70,498 patients met the study criteria.
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Table 1
Baseline characteristics of patients with atrial fibrillation newly-initiating anticoagulation, 2010-2012
Baseline Characteristic Warfarin Dabigatran Rivaroxaban
Sample size 43865 (62.2%) 21,070 (29.9%) 5563 (7.9%)
Age (years)
    < 55 3886 (8.9%) 2963 (14.1%) 796 (14.3%)
    55-64 10146 (23.1%) 6443 (30.6%) 1762 (31.7%)
    65-74 9792 (22.3%) 4838 (23.0%) 1233 (22.6%)
    ≥ 75 20041 (45.7%) 6826 (32.4%) 1772 (31.9%)
Male Gender 25562 (58.3%) 13363 (63.4%) 3409 (61.3%)
Region
    Northeast 7589 (17.3%) 3513 (16.7%) 808 (14.5%)
    North Central 15408 (35.1%) 6107 (29.0%) 1609 (28.9%)
    South 12181 (27.8%) 7,864 (37.3%) 2288 (41.1%)
    West 7732 (17.6%) 3259 (15.5%) 782 (14.1%)
Insurance plan
    Comprehensive 15701 (35.8%) 6812 (32.3%) 1716 (30.9%)
    Health maintenance organization 6368 (14.5%) 1723 (8.2%) 404 (7.3%)
    Point-of-service 1973 (4.5%) 1226 (5.8%) 264 (4.8%)
    Preferred provider organization 16689 (38.5%) 9766 (46.4%) 2715 (48.8%)
    Consumer driven health plan 707 (1.6%) 464 (2.2%) 113 (2.0%)
Ischemic Stroke 4710 (10.7%) 1495 (7.1%) 338 (6.1%)
Heart Failure 12414 (28.3%) 3851 (18.3%) 966 (17.4%)
Venous thromboembolism 5385 (12.3%) 538 (2.6%) 136 (2.4%)
Hyperlipidemia 21710 (49.5%) 10456 (49.6%) 2966 (53.3%)
Hypertension 32043 (73.1%) 14578 (69.2%) 4028 (72.4%)
Myocardial infarction 2001 (4.6%) 500 (2.4%) 141 (2.5%)
Coronary artery disease 15000 (34.2%) 5942 (28.2%) 1576 (28.3%)
Peripheral vascular disease 3892 (8.9%) 1150 (5.5%) 316 (5.7%)
Renal impairment 5517 (12.6%) 1210 (5.7%) 362 (6.5%)
Diabetes 13957 (31.8%) 5610 (26.6%) 1432 (25.7%)
Major bleeding 5975 (13.6%) 1983 (9.4%) 581 (10.4%)
Anemia 8736 (19.9%) 2241 (10.6%) 730 (13.1%)
Peptic Ulcer disease 320 (0.7%) 93 (0.4%) 31 (0.6%)
Sleep Apnea 4546 (10.4%) 2526 (12.0%) 738 (13.3%)
Cognitive deficiency 438 (1.0%) 126 (0.6%) 34 (0.6%)
Hospitalizations (≥1) 25231 (57.5%) 9431 (44.8%) 2597 (46.7%)
Catheter ablation 391 (0.9%) 459 (2.2%) 102 (1.8%)
Antiplatelet therapy 5726 (13.1%) 2684 (12.7%) 736 (13.2%)
Gastroprotective agent 5558 (12.7%) 2267 (10.8%) 683 (12.3%)
Antiarrhythmic 9991 (22.8%) 5344 (25.4%) 1482 (26.6%)
Digoxin 7435 (17.0%) 2973 (14.1%) 748 (13.5%)
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Baseline Characteristic Warfarin Dabigatran Rivaroxaban
Sample size 43865 (62.2%) 21,070 (29.9%) 5563 (7.9%)
Beta-blocker 29513 (67.3%) 14132 (67.1%) 3728 (67.1%)
Calcium channel blocker 18501 (42.2%) 8602 (40.8%) 2304 (41.4%)
Angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker 25001 (57.0%) 11891 (56.4%) 3149 (56.6%)
Statin 23964 (53.6%) 11205 (53.2%) 2907 (52.3%)
Hormone 1626 (3.7%) 959 (4.6%) 258 (4.6%)
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Table 2
Clinical prediction risk scores, prescription benefits and anticoagulant selection among patients with atrial 
fibrillation newly-initiating anticoagulation, 2010-2012
Warfarin (N=43,865) Dabigatran (N=21,070) Rivaroxaban (N=5,563)
Risk Score
CHA2DS2-VASC (Ischemic stroke risk)
    0 2182 (5.0%) 1881 (8.9%) 489 (8.8%)
    1 5121 (11.7%) 3981 (18.9%) 1068 (19.2%)
    ≥2 36562 (83.4%) 15208 (72.2%) 4006 (72.0%)
Mean (SD) 3.34 (1.81) 2.69 (1.72) 2.69 (1.73)
ATRIA (Bleeding risk)
    <4 30667 (69.9%) 17602 (83.5%) 4482 (80.6%)
    4 4158 (9.5%) 1501 (7.1%) 454 (8.2%)
    ≥5 9040 (20.6%) 1967 (9.3%) 627 (11.3%)
Mean (SD) 2.87 (2.39) 1.98 (1.89) 2.11 (2.01)
Prescription benefits
Benefits' generosity
    None/poor 1,625 (3.7%) 61 (0.3%) 23 (0.4%)
    Fair 21,410 (48.8%) 9769 (46.4%) 2500 (44.9%)
    Good 19,595 (44.7%) 10,611 (50.4%) 2,896 (52.1%)
Mean (SD) 0.27 (0.21) 0.21 (0.14) 0.21 (0.14)













Lauffenburger et al. Page 14
Table 3
Association between clinical risk scores, costs, and anticoagulant selection among patients newly-initiating 
anticoagulation
Novel oral anticoagulant vs. Warfarin (referent)
§
Rivaroxaban vs. Dabigatran (referent)
§†
Predictive factor Adjusted relative Risk 95% CI Adjusted relative risk 95% CI
CHA2DS2-VASC (ref: 0)
    1 0.95
0.91-0.98
** 1.00 0.92-1.09














Benefits' generosity (ref: none/poor)
    Fair (0.20-<0.80) 1.79
1.69-1.90
** 1.11 0.98-1.27




Adjusted for all other measured baseline covariates, except for those already included in risk scores
†
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Table 4
Treatment selection driven by clinical prediction risk scores and prescription benefits' generosity among 
patients with atrial fibrillation newly-initiating anticoagulation
Model C-statistic Change in c-statistic (95% CI) Chi-square for full model
§ Partial chi-square
Warfarin v. novel oral anticoagulants
Full Model with all covariates
§ 0.679 - 5635.021 -


















Full Model with all covariates
§ 0.557 - 139.126 -
Subtracting variables of interest:






- Benefits' generosity measure 0.556 −0.001 (−0.001, 0.002) - 2.889
§






Analysis restricted to when both were approved for atrial fibrillation
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